An AN OBSERVATIONAL STUDY OF LIVER FUNCTIONS IN MULTIPLE TRANSFUSED THALASSEMIA PATIENTS ON REGULAR CHELATION THERAPY VERSUS IRREGULAR CHELATION THERAPY IN A TERTIARY CARE CENTER OF JAIPUR, RAJASTHAN

RAJVEER SINGH YADAV; NIKITA PAL; TRAPTA GOYAL; SANDIP RAY; SHWETA YADAV; ABHISHEK KUMAR SHARMA

doi:10.22159/ajpcr.2024.v17i5.50630

Authors

RAJVEER SINGH YADAV Department of Pediatrics, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India https://orcid.org/0009-0003-6428-6108
NIKITA PAL Department of Pediatrics, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India https://orcid.org/0009-0008-4805-7280
TRAPTA GOYAL Department of Pediatrics, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
SANDIP RAY Department of Pediatrics, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India https://orcid.org/0000-0001-6091-7249
SHWETA YADAV Raj Child and Dental Clinic, Jaipur, Rajasthan, India.
ABHISHEK KUMAR SHARMA Department of Pediatrics, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India https://orcid.org/0000-0002-2358-1923

DOI:

https://doi.org/10.22159/ajpcr.2024.v17i5.50630

Keywords:

halassemia, Chelation therapy,, Multiple transfusion, Liver function

Abstract

Objectives: The aim of our study was to determine liver functions in thalassemia patients on regular versus irregular chelation therapy.

Methods: This was an observational study conducted in the department of pediatrics in a tertiary care hospital, Jaipur, Rajasthan. All those patients who received more than 50 blood transfusions are considered as multiple transfused patients and were included in this study.

Results: A total of 50 patients were enrolled in this study. Ninety percent of patients were under 15 years of age and the male-to-female ratio was 2.85:1. In 82.35% regular chelation therapy, patients have normal liver functions as compared to 49.5% in irregular chelation therapy patients.

Conclusion: Patients having abnormal liver functions in thalassemia patients due to iron overload. As a result of chelation therapy, serum glutamic oxalocetic transaminase and serum glutamic pyruvic transaminase levels were significantly reduced. In the study, regular chelation therapy should be started as early as indicated in thalassemia patients.

Downloads

Download data is not yet available.

References

Wetheal C. Thalassemia Syndrome. 2nd ed. Wiley Blackwell; 1981. p. 1-5.

Behrman RE, Kliegman R, Jenson HB. Nelson Text Book of Pediatrics. 17th ed., Vol. 1630. Philadelphia, PA: Saunders; 2004.

Cotran RS, Robbins SL, Kumar V. Robbins Pathology Basis of Disease. 6th ed. Philadelphia, PA: WB Saunders; 1994. p. 596-600.

Loscalzo J, Fauci A, Kasper D, Hauser S. Harrison’s Principles of Internal Medicine. 14th ed., Vol. 1. United States; Mcgraw-Hill; 1998 p. 650-1.

Ghai OP, Gupta P, Paul VK. Gai Essential Pediatrics. 6th ed. New Delhi: CBS Distributors and Publishers; 2004. p. 309-11.

Miller DR. Blood Disease of Infancy and Childhood. 7th ed. United States: Mosby; 1994. p. 475-9.

Olivieri NF, Brittenham GM. Iron chelating therapy and treatment of thalassemia. Blood. 1997;89:739-61.

Cossart YE, Kirsch S, Ismay SL. Post transfused hepatitis in Australia. Lancet. 1982;23:208-13.

Logothetis J, Constantoulakis M, Economidou J, Stefanis C, Hakas P, Augoustaki O, et al. Thalassemia major (homogenous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology. 1972;22:294-304.

Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, et al. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving transfusions. Vox Sang. 2003;84:292-9.

Manglani M, Lokeshwar MR, Vani VG, Bhatia N, Mhaskar V. Nestroft - an effective screening test for beta thalassemia trait. Indian Pediatr. 1997;34(8):702-7. PMID 9492398

Al- Kataan, Mohammad A, Shaimaa D, Al-Shakarchi. Changes of liver function tests with regular and irregular desferroxamine therapy in Beta-thalassemia patients. Zanco J Med Sci. 2010;14:166-9.

Hoffbrand AV, Gorman A, Laulicht M, Garidi M, Economidou J, Georgipoulou P, et al. Improvement in iron status and liver function in patients with transfusional iron overload with long term subcutaneous deseferroxamine. Lancet. 1947;1:947-9.

Beatrix W, M A Aldouri, A V Hoffbrand, D M Flynn, M Laulichi, L A Fenton, et al. Iron state and hepatic disease in patients with thalassemia major, related with long term subcutaneous deseferroxamine. J Clin Pathol. 1987;40:1353-9.